Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 1994 Mar; :1-9
Link
NIOSHTIC No.
00234645
Abstract
The potential use of leukocytes in circulation and in culture as exposure indicators, biomonitors of target tissue damage, and as predictors of risk of arylamine induced carcinogenesis was investigated. DNA of circulating mouse leukocytes formed adducts with metabolites of 2-aminofluorene (153786) (AF) following exposure to the carcinogen. These DNA adducts could be detected as soon as 3 hours after exposure. The concentration of leukocyte adducts declined in parallel with adducts in the liver, a target organ for arylamine carcinogenesis. DNA adducts in the urinary bladder also declined in an irregular course not correlated to the leukocyte decline. Chronic exposure for 7 days produced high amounts of leukocyte AF-DNA adducts. Studies indicated that the metabolism of AF and the formation of adducts in cultured mononuclear leukocytes (MNL) occurred in a time and dose dependent manner. A dependence of bladder DNA damage by AF in mice on the acetylation phenotype, the age at exposure, and the sex of the mice was found. Evidence was also reported for the formation of a bladder adduct by prostaglandin- synthase activation of AF. Cloned mouse N-acetyltransferases were expressed in COS-1 cells to determine the substrate specificity and other properties of the enzymes. The finding that both enzymes can acetylate the arylamine carcinogen AF means that DNA adduct formation is possible in any tissue having either isozyme of N- acetyltransferase. Thirty five tissues were examined for AF acetylating activity. In all tissues studied, except blood plasma and seminal vesicles, significant activity was noted. Among the higher levels of activity were those found in leukocytes. Mouse colon demonstrated the same genetic polymorphism in N-acetylation activity as reported for the liver, indicating that the inbred mouse may be a model for studies of human colon cancer which has been linked to N-acetylation phenotype.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.